Humacyte (Humacyte) ROCE % : -93.58% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Humacyte ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Humacyte's annualized ROCE % for the quarter that ended in Mar. 2024 was -93.58%.

Humacyte ROCE % Historical Data

The historical data trend for Humacyte's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte ROCE % Chart

Humacyte Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-67.38

-11.93

-2.51

-70.75

Humacyte Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial										-82.00	-53.14	-67.45	-76.64	-93.58

Humacyte ROCE % Calculation

Humacyte's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-104.177	/	( ( (204.302 - 19.58)	+	(128.223 - 18.443) )	/ 2 )
	=	-104.177	/	( (184.722	+	109.78)	/ 2 )
	=	-104.177	/	147.251
	=	-70.75 %

Humacyte's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-120.32	/	( ( (128.223 - 18.443)	+	(161.466 - 14.087) )	/ 2 )
	=	-120.32	/	( ( 109.78	+	147.379 )	/ 2 )
	=	-120.32	/	128.5795
	=	-93.58 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Humacyte (NAS:HUMA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Humacyte ROCE % Related Terms

Thank you for viewing the detailed overview of Humacyte's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Humacyte (Humacyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2525 East North Carolina Highway 54, Durham, NC, USA, 27713

Website

https://www.humacyte.com

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Executives

Laura E Niklason	director, 10 percent owner, officer: President, CEO and Director	35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan	director, 10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Ayabudge Llc	10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard	officer: Chief Operating Officer	820 BROWNWICH STREET, WAKE FOREST NC 27587
Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Dale A. Sander	officer: CFO & CCDO	11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
William John Scheessele	officer: Chief Commercial Officer	620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao	officer: Chief Regulatory Officer	12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green	director	3185 SCENIC DRIVE, NAPA CA 94558
Gordon M Binder	director	225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Diane Seimetz	director	JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh	officer: Chief Medical Officer	1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla	director	EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
William Edward Tente	officer: Chief Regulatory Officer	90 DAVIS STREET, SEEKONK MA 02771
Todd Pope	director	C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713